Skip to main content
Top
Published in: Journal of General Internal Medicine 6/2008

01-06-2008 | Original Article

Medicare Beneficiaries and Free Prescription Drug Samples: A National Survey

Authors: Jennifer Tjia, MD, MSCE, Becky A. Briesacher, PhD, Stephen B. Soumerai, ScD, Marsha Pierre-Jacques, BA, Fang Zhang, PhD, Dennis Ross-Degnan, ScD, Jerry H. Gurwitz, MD

Published in: Journal of General Internal Medicine | Issue 6/2008

Login to get access

ABSTRACT

Background

New policies regulating physician/pharmaceutical company relationships propose to eliminate access to free prescription drug samples. Little is known about the prevalence of patient activity in requesting or receiving free prescription drug samples, or the characteristics of patients who access drug samples.

Objective

To determine the prevalence of free sample access and to examine demographic, clinical, and insurance characteristics of Medicare beneficiaries who access free samples.

Design

Cross-sectional study.

Participants

A national sample of 13,847 Medicare beneficiaries participating in the fall 2004 Medicare Current Beneficiary Survey.

Measurements and Main Results

Prevalence of free prescription drug sample access (self-reported request for or receipt of free drug samples) and the demographic, clinical, and insurance characteristics of Medicare beneficiaries who accessed drug samples. Overall, 48.3% (95% confidence of interval [CI]: 46.6%, 49.9%) of Medicare beneficiaries reported accessing free drug samples. Access was higher among beneficiaries reporting cost-related medication nonadherence compared to those without (77.7% (95% CI: 74.5%, 80.6%) vs 43.0% (95% CI: 41.4%, 44.7%)). Multivariable analysis revealed cost-related medication nonadherence (CRN) to have the strongest relationship with accessing drug samples (adjusted odds ratio [AOR] 4.43 [95% CI: 3.64, 5.39]). Compared to beneficiaries with generous drug benefits from Medicaid, beneficiaries who lacked prescription drug benefits were more likely to access drug samples (AOR 2.42 [95% CI: 2.06, 2.85]). Beneficiaries with drug coverage from employer-sponsored plans or partial coverage (Medicare HMO, self-purchased Medicare supplement, or state-sponsored low-income plans) were also more likely to access drug samples (AOR 2.02, 1.74, respectively). Having 2–3 or ≥4 comorbidities (vs 0–1 comorbidities) also increased the likelihood of accessing drug samples (AOR 1.60 (95% CI: 1.44, 1.79) and 2.00 (95% CI: 1.74, 2.29).

Conclusions

Accessing free prescription drug samples is prevalent among many categories of beneficiaries, especially among individuals with cost-related medication nonadherence and poor health status. Policies restricting or prohibiting drug sample distribution may adversely impact access to medications among patients in high-risk groups.
Literature
2.
go back to reference Coleman DL, Kazdin AE, Miller LA, Morrow JS, Udelsman R. Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school’s approach. Acad Med. 2006;81:154–60.PubMedCrossRef Coleman DL, Kazdin AE, Miller LA, Morrow JS, Udelsman R. Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school’s approach. Acad Med. 2006;81:154–60.PubMedCrossRef
5.
go back to reference Policy and Guidelines for Interactions between the Stanford University School of Medicine, the Stanford Hospital and Clinics, and Lucile Packard Children’s Hospital with the Pharmaceutical, Biotech, Medial Device, and Hospital and Research Equipment and Supplies Industries (“Industry”): Stanford Hospital and Clinics; 2006. http://med.stanford.edu/coi/siip/policy.html Accessed on February 20, 2008. Policy and Guidelines for Interactions between the Stanford University School of Medicine, the Stanford Hospital and Clinics, and Lucile Packard Children’s Hospital with the Pharmaceutical, Biotech, Medial Device, and Hospital and Research Equipment and Supplies Industries (“Industry”): Stanford Hospital and Clinics; 2006. http://​med.​stanford.​edu/​coi/​siip/​policy.​html Accessed on February 20, 2008.
7.
go back to reference Soumerai SB, Pierre-Jacques M, Zhang F, et al. Cost-related medication nonadherence among elderly and disabled Medicare beneficiaries: a national survey one year before the medicare drug benefit. Arch Intern Med. 2006;166:1829–35.PubMedCrossRef Soumerai SB, Pierre-Jacques M, Zhang F, et al. Cost-related medication nonadherence among elderly and disabled Medicare beneficiaries: a national survey one year before the medicare drug benefit. Arch Intern Med. 2006;166:1829–35.PubMedCrossRef
8.
go back to reference Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood). Jan–Jun 2005;Suppl Web Exclusives:W5-152-W155-166. Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: findings from a 2003 national survey. Health Aff (Millwood). Jan–Jun 2005;Suppl Web Exclusives:W5-152-W155-166.
9.
go back to reference Government Accountability Office. Table 1. Prescription Drug Promotion and Research and Development, 1997 through 2005 in GAO-07-54 Report to Congressional Requesters. Prescription Drugs: Improvements Needed in FDA’s Oversight of Direct-to-Consumer Advertising. United States Government Accountability Office. November 2006. Government Accountability Office. Table 1. Prescription Drug Promotion and Research and Development, 1997 through 2005 in GAO-07-54 Report to Congressional Requesters. Prescription Drugs: Improvements Needed in FDA’s Oversight of Direct-to-Consumer Advertising. United States Government Accountability Office. November 2006.
10.
go back to reference Chew LD, O’Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A physician survey of the effect of drug sample availability on physicians’ behavior. J Gen Intern Med. 2000;15:478–83.PubMedCrossRef Chew LD, O’Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS. A physician survey of the effect of drug sample availability on physicians’ behavior. J Gen Intern Med. 2000;15:478–83.PubMedCrossRef
11.
go back to reference Zweifler J, Hughes S, Schafer S, Garcia B, Grasser A, Salazar L. Are sample medicines hurting the uninsured? J Am Board Fam Pract. 2002;15:361–6.PubMed Zweifler J, Hughes S, Schafer S, Garcia B, Grasser A, Salazar L. Are sample medicines hurting the uninsured? J Am Board Fam Pract. 2002;15:361–6.PubMed
12.
go back to reference Taira DA, Iwane KA, Chung RS. Prescription drugs: elderly beneficiary reports of financial access, receipt of drug samples, and discussion of generic equivalents related to type of coverage. Am J Manag Care. 2003;9(4):305–12.PubMed Taira DA, Iwane KA, Chung RS. Prescription drugs: elderly beneficiary reports of financial access, receipt of drug samples, and discussion of generic equivalents related to type of coverage. Am J Manag Care. 2003;9(4):305–12.PubMed
15.
go back to reference Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373–80.PubMedCrossRef Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373–80.PubMedCrossRef
16.
go back to reference Adler GS. A profile of the Medicare Current Beneficiary Survey. Health Care Financ Rev. 1994;15:153–63.PubMed Adler GS. A profile of the Medicare Current Beneficiary Survey. Health Care Financ Rev. 1994;15:153–63.PubMed
18.
go back to reference DeSalvo KB, Fan VS, McDonell MB, Fihn SD. Predicting mortality and healthcare utilization with a single question. Health Serv Res. 2005;40:1234–46.PubMedCrossRef DeSalvo KB, Fan VS, McDonell MB, Fihn SD. Predicting mortality and healthcare utilization with a single question. Health Serv Res. 2005;40:1234–46.PubMedCrossRef
20.
go back to reference Adams AS, Soumerai SB, Ross-Degnan D. Use of antihypertensive drugs by Medicare beneficiaries: does type of drug coverage matter? Health Aff (Millwood). 2001;20:276–86.CrossRef Adams AS, Soumerai SB, Ross-Degnan D. Use of antihypertensive drugs by Medicare beneficiaries: does type of drug coverage matter? Health Aff (Millwood). 2001;20:276–86.CrossRef
21.
go back to reference Centers for Medicare and Medicaid Services. Technical Documentation for the Medicare Current Beneficiary Survey, MCBS, 2003 Access to Care, Section 5: Sample Design and Guidelines for Preparing Statistics 2003. [Book on CD-ROM]. Baltimore, MD: Center for Medicare and Medicaid Services, Office of the Actuary; 2005. Centers for Medicare and Medicaid Services. Technical Documentation for the Medicare Current Beneficiary Survey, MCBS, 2003 Access to Care, Section 5: Sample Design and Guidelines for Preparing Statistics 2003. [Book on CD-ROM]. Baltimore, MD: Center for Medicare and Medicaid Services, Office of the Actuary; 2005.
22.
go back to reference Korn E, Graubard B. Analysis of Health Surveys. New York: Wiley & Sons, Inc; 1999. Korn E, Graubard B. Analysis of Health Surveys. New York: Wiley & Sons, Inc; 1999.
23.
go back to reference Archer K, Lemeshow S. Goodness-of-fit test for a logistic regression model fitted using survey sample data. Stata Journal. 2006;5:97–105. Archer K, Lemeshow S. Goodness-of-fit test for a logistic regression model fitted using survey sample data. Stata Journal. 2006;5:97–105.
24.
go back to reference Cutrona SL, Woolhandler S, Lasser KE, et al. Characteristics of recipients of free prescription drug samples: a nationally representative analysis. Am J Public Health. 2008;98:284–89.PubMedCrossRef Cutrona SL, Woolhandler S, Lasser KE, et al. Characteristics of recipients of free prescription drug samples: a nationally representative analysis. Am J Public Health. 2008;98:284–89.PubMedCrossRef
25.
go back to reference Piette JD, Heisler M, Wagner TH. Cost-related medication underuse: do patients with chronic illnesses tell their doctors? Arch Intern Med. 2004;164:1749–55.PubMedCrossRef Piette JD, Heisler M, Wagner TH. Cost-related medication underuse: do patients with chronic illnesses tell their doctors? Arch Intern Med. 2004;164:1749–55.PubMedCrossRef
26.
go back to reference Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291:2344–50.PubMedCrossRef Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291:2344–50.PubMedCrossRef
27.
go back to reference Tseng CW, Brook RH, Keeler E, Mangione CM. Impact of an annual dollar limit or “cap” on prescription drug benefits for Medicare patients. JAMA. 2003;290:222–7.PubMedCrossRef Tseng CW, Brook RH, Keeler E, Mangione CM. Impact of an annual dollar limit or “cap” on prescription drug benefits for Medicare patients. JAMA. 2003;290:222–7.PubMedCrossRef
28.
go back to reference Soumerai SB, Avorn J, Ross-Degnan D, et al. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med. 1987;317:550–6.PubMedCrossRef Soumerai SB, Avorn J, Ross-Degnan D, et al. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med. 1987;317:550–6.PubMedCrossRef
29.
go back to reference Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician–industry relationships. N Engl J Med. 2007;56:1742–50.CrossRef Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician–industry relationships. N Engl J Med. 2007;56:1742–50.CrossRef
30.
go back to reference Rabin R. Free Drug Samples? Bad Idea, Some Say. New York Times. May 1, 2007. Rabin R. Free Drug Samples? Bad Idea, Some Say. New York Times. May 1, 2007.
31.
go back to reference Stuart B, Briesacher BA, Shea DG, Cooper B, Baysac FS, Limcangco MR. Riding the rollercoaster: the ups and downs in out-of-pocket spending under the standard Medicare drug benefit. Health Aff (Millwood). 2005;4:1022–31.CrossRef Stuart B, Briesacher BA, Shea DG, Cooper B, Baysac FS, Limcangco MR. Riding the rollercoaster: the ups and downs in out-of-pocket spending under the standard Medicare drug benefit. Health Aff (Millwood). 2005;4:1022–31.CrossRef
32.
go back to reference Tjia J, Schwartz J. Will the Medicare prescription drug benefit eliminate cost barriers for older adults with diabetes mellitus? J Am Geriatr Soc. 2006;4:606–12.CrossRef Tjia J, Schwartz J. Will the Medicare prescription drug benefit eliminate cost barriers for older adults with diabetes mellitus? J Am Geriatr Soc. 2006;4:606–12.CrossRef
Metadata
Title
Medicare Beneficiaries and Free Prescription Drug Samples: A National Survey
Authors
Jennifer Tjia, MD, MSCE
Becky A. Briesacher, PhD
Stephen B. Soumerai, ScD
Marsha Pierre-Jacques, BA
Fang Zhang, PhD
Dennis Ross-Degnan, ScD
Jerry H. Gurwitz, MD
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 6/2008
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-008-0568-2

Other articles of this Issue 6/2008

Journal of General Internal Medicine 6/2008 Go to the issue

Reflection

Shoulder Song

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.